ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 643

Mir-10b-5p Is a IL-22 Regulator in CD4+T Cells from Ankylosing Spondylitis

Tae-Jong Kim1, So-Hee Jin2, Liye Chen3, Mohammad Hussein Al-Mossawi3, Anna Ridley3, Takuya Sekine3, Davide Simone3, Hui Shi3, Frank Penkava3 and Paul Bowness3, 1Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, Korea, Republic of (South), 2Chonnam National University Medical School and Hospital, Gwangju, Korea, Republic of (South), 3Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: MicroRNA and ankylosing spondylitis (AS)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Spondyloarthropathies and Psoriatic Arthritis – Pathogenesis, Etiology Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Emerging data suggest that a single microRNA (miR) can profoundly alter the phenotype and outcome of immune responses, offering the prospect of therapeutic use. We recently reported a novel Th17 regulator miR-10b-5p that is present in Th17 cells from patients with Ankylosing Spondylitis (AS). IL-22 is closely related to Th17 cells and also regulated by IL-23, a key cytokine for IL-17A production. Moreover, IL-22 has been implicated in the regulation of new bone formation in experimental models. Therefore, we wonder whether miR-10b-5p affects IL-22 production in AS.

Methods:

Primary CD4+ T cells were negatively isolated from PBMCs from AS patients (Miltenyi Biotec). Transfection was performed with the Neon transfection system (Thermos Fisher Scientific, Germany) according to manufacturer’s instructions.

The transfection efficiency was evaluated by monitoring FAM (Fluorescein) positive cells using flow cytometry, and qPCR at 24 h after transfection. miR-10b-5p function was determined by overexpression of miR mimic in CD4+ T cells followed by intracellular cytokine staining, cytokine measurement, and qPCR. Statistical analysis was performed using Prism 5.0 Software (GraphPad Software, San Diego, USA). A p < 0.05 was considered statistically significant.

Results:

Overexpression of miR-10b-5p reduced both IL-22+CD4+ T cell frequencies and IL-22 production in CD4+ T cells from patients with AS. To identify the cellular targets of miR-10b-5p, we previously performed RNA-sequencing of CD4+ T cells transfected with miR-10b-5p together with in silico Target Scan analysis. MAP3K7 was selected as a target gene because of its known role in cytokine regulation. We then silenced MAP3K7 in CD4+ T cells using siRNA and found the suppression of IL-22 response, mimicking the effect of miR-10b-5p overexpression.

Conclusion:

Our data suggest that miR-10b-5p suppress IL-22 production by targeting MAP3K7. miR-10b-5p might be a potential therapeutic candidate for regulation of new bone formation in patients with AS.


Disclosure: T. J. Kim, None; S. H. Jin, None; L. Chen, None; M. H. Al-Mossawi, None; A. Ridley, None; T. Sekine, None; D. Simone, None; H. Shi, None; F. Penkava, None; P. Bowness, None.

To cite this abstract in AMA style:

Kim TJ, Jin SH, Chen L, Al-Mossawi MH, Ridley A, Sekine T, Simone D, Shi H, Penkava F, Bowness P. Mir-10b-5p Is a IL-22 Regulator in CD4+T Cells from Ankylosing Spondylitis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/mir-10b-5p-is-a-il-22-regulator-in-cd4t-cells-from-ankylosing-spondylitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mir-10b-5p-is-a-il-22-regulator-in-cd4t-cells-from-ankylosing-spondylitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology